Cardiovascular events in patients with antiphospholipid antibodies: Strategies of prevention

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 20, Issue 4, 2010, Pages 217-223

  Tufano, A ^a   Guida, A ^a   Di Minno, M N D ^a   De Gregorio, A M ^a   Cerbone, A M ^a   Di Minno, Giovanni ^a  

^a FEDERICO II UNIVERSITY HOSPITAL   (Italy)

Author keywords

Antiphospholipid antibodies; Aspirin; Cardiovascular disease; Primary prophylaxis; Systemic lupus erythematosus

Indexed keywords

ANTICOAGULANT AGENT; PHOSPHOLIPID ANTIBODY;

ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR DISEASE; HUMAN; SHORT SURVEY; THROMBOEMBOLISM;

ANTIBODIES, ANTIPHOSPHOLIPID; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; CARDIOVASCULAR DISEASES; HUMANS; THROMBOEMBOLISM;

EID: 77950863839     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2009.10.016     Document Type: Short Survey

References (42)

1. Levine J.S., Branch D.W., and Rauch J. The antiphospholipid syndrome. N Engl J Med 346 (2002) 752-763
2. Bertolaccini M.L., Khamashta M.A., and Hughes R.V. Diagnosis of antiphospholipid syndrome. Nat Clin Pract Rheumatol 1 (2005) 40-46
3. Lockshin M.D. Update on antiphospholipid syndrome. Bull NYU Hosp Joint Dis 66 (2008) 195-197
4. Cuadrado M.J., and Lopez-Pedrera C. Antiphospholipid syndrome. Clin Exp Med 3 (2003) 129-139
5. De Groot P.G., and Derksen H.W.M. Pathophysiology of the antiphospholipid syndrome. J Thromb Haemost 3 (2005) 1854-1860
6. Giron-Gonzalez J.A., Garcia del Rio E., Rodriguez C., Rodriguez-Martorell J., and Serrano A. Antiphospholipid syndrome and asymptomatic carriers of antiphospholipid antibody: prospective analysis of 404 individuals. J Rheumatol 31 (2004) 1560-1567
7. Triplett D.A.A. Antiphospholipid-protein antibodies: laboratory detection and clinical relevance. Thromb Res 78 (1995) 1-31
8. Lim W., Crowther M.A., and Eikelboom J.W. Management of antiphospholipid antibody syndrome. A systematic review. JAMA 295 (2006) 1050-1057
9. Basili S., and Violi F. Aspirin in asymptomatic patients with a confirmed positivity of antiphospholipid antibodies. Intern Emerg Med 3 (2008) 373-374
10. Finazzi G., Brancaccio V., Moia M., Ciaravella N., Mazzucconi M.G., Schinco P.C., et al. Natural history and risk factors for thrombosis in 360 patients with antiphospholipid antibodies. A four-year prospective study from the Italian registry. Am J Med 100 (1996) 530-536
11. Forastiero R., Martinuzzo M., Pombo G., Puente D., Rossi A., Celebrin L., et al. A prospective study of antibodies to anti β2-glycoprotein I and prothrombin and risk of thrombosis. J Thromb Haemost 3 (2005) 1231-1238
12. Ginsburg K.S., Liang M.H., Newcomer L., Goldhaber S.Z., Schur P.H., Hennekens C.H., and Stampfer M.J. Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117 (1992) 997-1002
13. Somers E., Magder L.S., and Petri M. Antiphospholipid antibodies and incidence of venous thrombosis in a cohort of patients with systemic lupus erythematosus. J Rheumatol 29 (2002) 2531-2536
14. Tarr T., Lakos G., Bhattoa H.P., Shoenfeld Y., Szegedi G., and Kiss E. Analysis of risk factors for the development of thrombotic complications in antiphospholipid antibody positive lupus patients. Lupus 16 (2007) 39-45
15. Tektonidou M.G., Laskari K., Panagiotakos B., and Moutsopoulos H.M. Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies. Arthritis Rheum 61 (2009) 29-36
16. Long A.A., Ginsberg J.S., Brill-Edwards P., Johnston M., Turner C., Denburg J.A., et al. The relationship of antiphospholipid antibodies to thromboembolic disease in systemic lupus erythematosus: a cross-sectional study. Thromb Haemost 66 (1991) 520-524
17. Khamasiita M.A., Guadrado M.J., Mujic F., Taub N.A., Hunt B.J., and Hugiies G.R.V. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 332 (1995) 993-997
18. Rosove M.H., Tabsh K., Wasserstrum N., Howard P., Hahn B.H., and Kalunian K.C. Heparin therapy for pregnancy women with lupus anticoagulant or anticardiolipin antibodies. Obstet Gynecol 75 (1990) 630-634
19. Rosove M.H., and Brewer P.M.C. Antiphospholipid thrombosis: clinical course after the first thrombotic event in 70 patients. Ann Intern Med 117 (1992) 303-308
20. Derksen R.H., de Groot P.G., Kater L., and Nieuwenhuis H.K. Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52 (1993) 689-692
21. Salmon J.E., Girardi G., and Lockshin M.D. The antiphospholipid syndrome as a disorder initiated by inflammation: implications for the therapy of pregnant patients. Nat Clin Pract Rheumatol 3 (2007) 140-147
22. Crowter M.A., Ginsberg J.S., Julian J., Denburg J., Hirsh J., Douketis j., et al. A comparison of two intensities of warfarin for the prevention or recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 349 (2003) 1133-1138
23. Moll S., and Ortel T.L. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 127 (1997) 177-185
24. Galli M. Aspirin thromboprophylaxis of asymptomatic antiphospholipids-positive subjects. Intern Emerg Med 4 (2009) 63-64
25. Erkan D., Merrill J.T., Yazici Y., Sammaritano L., Buyon J.P., and Lockshin M.D. High thrombosis rate after fetal loss in antiphospholipid syndrome: effective prophylaxis with aspirin. Arthritis Rheum 44 (2001) 1466-1467
26. Erkan D., Harrison M.J., Levy R., Peterson M., Petri M., Sammaritano L., et al. A randomized double-blind placebo-controlled trial in asymptomatic antiphospholipid antibody positive individuals. Arthritis Rheum 56 (2007) 2382-2391
27. Gerosa M., Chighizola C., and Meroni P.L. Aspirin in asymptomatic patients with confirmed positivity of anticardiolipin antibodies? Yes (in some cases). Intern Emerg Med 3 (2008) 201-203
28. Finazzi G. Aspirin in asymptomatic patients with confirmed positivity of anticardiolipin antibodies? No. Intern Emerg Med 3 (2008) 197-200
29. Glynn R.J., Ridker P.M., Goldhaber S.Z., and Buring J.E. Effect of low-dose aspirin on the occurrence of venous thromboembolism: a randomized trial. Ann Intern Med 147 (2007) 525-533
30. Galli M., Finazzi G., Duca F., Norbis F., and moia M. The G1691A mutation of factor V, but not the G20210A mutation of factor II or the C677T mutation of methylenethetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br J Haematol 108 (2000) 865-870
31. Galli M., Luciani D., Bertolini G., and Barbui T. Lupus anticoagulants are stronger risk factors of thrombosis than anticardiolipin antibodies in the Antiphospholipid syndrome: a systematic review of the literature. Blood 101 (2003) 1827-1832
32. Galli M., Luciani D., Bertolini G., and Barbui T. Anti β2-glycoprotein I, antiprothrombin antibodies and the risk of thrombosis in the antiphospholipids syndrome. Blood 102 (2003) 2717-2723
33. Horbach D.A., van Oort E., Derksen R.H.W.H., and de Groot P.G. The contribution of anti-prothrombin antibodies to the lupus anticoagulant activity-discrimination between functional and non-function anti-prothrombin antibodies. J Thromb Haemost 79 (1998) 790-795
34. De Laat H.B., Derksen R.H.W.M., Urbanus R.T., Roest M., and de Groot P.G. β2-glycoprotein I-dependent lupus anticoagulant highly correlates with thrombosis in the antiphospholipid syndrome. Blood 104 (2004) 3598-3602
35. De Laat H.B., Derksen R.H.W.M., Urbanus R.T., and de Groot P.G. IgG antibodies that recognize epitope Gly40-Arg43 in domain I of β2-glycoprotein I cause LAC, and their presence correlates strongly with thrombosis. Blood 105 (2005) 1540-1545
36. Rix P., Stentoft J., Aunsholt N.A., Dueholm M., Tilma K.A., and Hoier-Madsen M. Lupus anticoagulant and anticardiolipin antibodies in an obstetric population. Acta Obstet Gynecol Scand 71 (1992) 605-609
37. Schved J.F., Dupuy-Fons C., Biron C., Quére I., and Janbon C. A prospective epidemiological study on the occurrence of antiphospholipids antibody: the Montpellier antiphospholipids (MAP) study. Haemostasis 24 (1994) 175-182
38. Andreoli L., and Tincani A. 25 years of the antiphospholipids syndrome; lights and shadows on the primary prophylaxis of asymptomatic patients with confirmed positivity of antiphospholipids antibodies. Intern Emerg Med 4 (2009) 165-167
39. Ras R. New approaches to prevention of thrombosis in the antiphospholipid syndrome: hopes, trials, and tribulations. Arthritis Rheum 48 (2003) 3004-3008
40. Rand J.H., Wu X.X., Quinn A.S., Chen P.P., Hathcock J.J., and Taatjes D.J. Hydroxychloroquine directly reduces the binding of antiphospholipid antibody- β2-glycoprotein I complexes to phospholipid bilayers. Blood 112 (2008) 1687-1695
41. Schillaci G., Pucci G., and Pirro M. The emerging role of atherosclerotic cardiovascular disease in systemic lupus erythematosus. Nutr Metab Cardiovasc Dis 19 (2009) 231-233
42. Palmieri V., Migliaresi P., Orefice M., Lupo T., Di Minno M.N., Valentini G., and Celentano A. High prevalence of subclinical abnormalities in patients with systemic lupus erythematosus in spite of a very low clinical damage index. Nutr Metab Cardiovasc Dis 19 (2009) 234-240